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Abstract
It is increasingly recognized that osteoporosis affects children as well as adults both as a primary
problem and as secondary to various diseases, medications, and lifestyle issues. In this review, we
emphasize the correct diagnosis of osteoporosis in children as opposed to adults, etiology, and
pharmaceutical and non-pharmaceutical treatments. We especially focus on rheumatologic
conditions associated with osteoporosis and management issues.
Introductory case 1
An 11-year-old, previously healthy girl presented with a
new fracture of the femoral bone following a mild sports
injury. Plain x-ray revealed an osteoporotic fracture. What
is the cause? What therapy is recommended for preventing
new fractures?
Introductory case 2
A 13-year-old boy was treated with corticosteroids for
juvenile idiopathic arthritis. Which therapy might be
helpful for reduction of osteoporosis? Later he developed
back pain and an osteoporotic fracture in the T7 vertebra
(Figure 1). Which therapy is suggested to prevent addi-
tional fractures?
Background
There is greater awareness and recognition of osteoporosis
(OP) in children both as a primary problem and as a har-
binger of OP in adulthood. Although it was once thought
to afflict mainly adults with chronic diseases and elderly
patients, in recent years OP has been recognized as a pedi-
atric problem as well.
In this article, we will review the common forms of pedi-
atric OP and emphasize the latest treatment data available
in the literature.
Definition and measuring osteoporosis
In adults, OP is commonly defined as a bone density of
2.5 standard deviations (SD) below the mean in dual
emission x-ray absorptiometry (DXA) [1]. Osteopenia is
defined as a bone density between 1.0 and 2.5 SD below
the young adult mean. In the pediatric population, a
somewhat different definition exists, requiring both a his-
tory of pathologic fractures and low bone mineral content
or density [2]. These criteria are fulfilled by the diagnosis
of a single significant fracture in a long bone of the lower
extremity, two fractures in the long bone of an upper
extremity, or one vertebral compression fracture.
Bone density varies greatly with age. This is the reason the
densitometry Z-score is used in the pediatric population
and not the T-score usually used in adults. Z scores of -2
SD define OP [3].
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The problem with pediatric DXA studies is the over-diag-
nosis of OP in children due to misinterpretation of data
based on adult references [4]. To help correct this misin-
terpretation, the Stanford reference graph was created
based on an evaluation of 423 healthy children from var-
ious ethnicities. It is currently used for children by con-
verting DXA data adjusted for age and sex http://www-
stat-class.stanford.edu/pediatric-bones/.
Other modes of assessing OP are ultrasound (US) by
measuring the bone speed of sound (SOS) at the tibial,
radial, or calcaneal bones reflecting both cortical density
and thickness [5-7] or quantitative computed tomography
(QCT) which can supplement DXA by enabling geometric
and compartmental bone assessments [8,9]. While US is
being used more frequently in pediatrics, QCT is less
known and DXA is the still considered gold standard for
assessing OP.
Common laboratory tests for evaluation of OP include
calcium, phosphate, bone alkaline phosphatase, vitamin
D levels (most common vitamin D25), parathyroid hor-
mone levels, and 24-hour urinary calcium and phosphate.
More specific bone turnover markers include serum PINP
(propeptide of type I procollagen) and carboxyterminal
(PICP) propeptides of type I collagen as bone formation
marker, and amino-terminal (NTX) and carboxyterminal
(CTX) telopeptides of type I collagen as bone resorption
markers.
Etiology
There are many possible causes for OP in children - most
are secondary to other illnesses or treatments, especially
glucocorticoid (GC) use (Table 1). The most common pri-
mary bone disorder leading to OP is osteogenesis imper-
fecta (OI), a structural genetic defect in the quantity or
quality of bone type 1 collagen production. OI has several
subtypes ranging from mild forms to that which causes
intrauterine fetal death. The family history, the blue, pur-
ple, or gray sclera commonly found in OI, radiographic
findings, and in some cases, bone biopsy help determine
the diagnosis.
Other primary bone causes of OP include idiopathic juve-
nile osteoporosis (IJO) [10], and osteoporosis-pseudogli-
oma syndrome; these two are rarely encountered.
Secondary causes of OP are much more common. There
are several subgroups, including systemic inflammatory
diseases which affect bone metabolism due to high
inflammatory cytokine levels and corticosteroid use and
endocrine disorders such as diabetes mellitus, hyperpar-
athyroidism, hyperthyroidism, hypercortisolism, and
hypogonadism that act via altered hormone levels. Any
cause of immobilization, such as in cerebral palsy or spi-
nal muscular atrophy, decreases bone density due to
diminished mechanical stimulation. Also important to
note are neoplastic disorders (especially leukemia and
lymphoma), medications such as GC, anticonvulsants,
and heparin. Finally, decreased dietary intake of calcium,
vitamin D deficiency, malabsorption, and a low calorie
diet in endurance athletes are additional risk factors for
OP.
Discoveries in recent years have disclosed other aspects of
bone turnover. The receptor activator of nuclear factor κB
(RANK) and its ligand (RANKL), along with another cel-
lular moiety - osteoprotegerin (OPG) - were found to be
important participants in osteoclast differentiation and
proliferation. While the activation of RANK with its ligand
molecule promotes osteoclast proliferation, the RANK
receptor OPG actually inhibits this process, subsequently
decreasing osteoclast activity and bone resorption. Muta-
tions in the OPG and RANK genes are responsible for two
Spine radiograph demonstrating an osteoporosis-related T7  vertebral fracture Figure 1
Spine radiograph demonstrating an osteoporosis-
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hereditary forms of primary bone disorder, namely juve-
nile Paget's disease and early-onset Paget's disease [11].
However, the RANK-RANKL-OPG system is also involved
in bone resorption due to systemic GC use. Administra-
tion of GC induces synthesis of RANKL and inhibits pro-
duction of OPG [12]. This may be the reason for
osteopenia and OP found after chronic use of these drugs.
GC also inhibit replication, differentiation and function
of osteoblasts and induce the apoptosis of mature osteob-
lasts and may inhibit bone building functions or calcium
absorption through nongenomic effects, for example by
interactions with biological membranes, either through
binding to membrane receptors or by physicochemical
interactions.
Systemic lupus erythematosus, juvenile idiopathic arthritis 
and dermatomyositis
Individuals with juvenile onset SLE are more prone to suf-
fer from decreased bone mineral density (BMD) and
hence OP [13,14]. Factors recognized to be responsible
for these effects are various cytokines and GC use, espe-
cially via the RANK-RANKL-OPG system. Compeyrot-
Lacassagne et al. [15] described prevalence values for oste-
openia and OP among juvenile SLE patients. In their
cohort, rates for osteopenia and OP were 37.5% and
20.3%, respectively. Factors associated with these condi-
tions were disease duration, use of GC and cytotoxic drugs
and disease severity, especially nephritis. Reported OP
rates were slightly lower at 12.1% in a large cohort of 1000
adult patients followed for 10 years [16]. Similar findings
have been reported for dermatomyositis [17]. While not
yet proven in comparative studies, it is the impression of
many clinicians that the OP of dermatomyositis may be
more severe than other autoimmune diseases even when
treated with the same type and dose of glucocorticoids.
Perhaps the relatively greater immobilization in myositis
may play a role, as well as a more prolonged/higher
cumulative dose.
Table 1: Etiology of Osteoporosis in Children.
Primary bone disorders Chronic inflammatory diseases
Osteogenesis imperfecta Systemic lupus erythematosus
Idiopathic juvenile osteoporosis Juvenile idiopathic arthritis
Osteoporosis-Pseudoglioma syndrome Dermatomyositis
Homocystinuria Inflammatory bowel disease
Ehlers-Danlos syndrome (type I) Nephrotic syndrome
Marfan syndrome Immobility or decreased activity
GSD type 1 Post trauma
Juvenile/Early-onset Paget's disease Cerebral palsy
Catabolic state/Inadequate nutrition/Malabsorption Spinal muscular atrophy, Muscular dystrophy
Vitamin D deficiency Medications
Malignancy - Acute lymphoblastic leukemia, Lymphoma Anticonvulsant, Glucocorticosteroids, Heparin, Methotrexate (in oncology doses)
Cystic fibrosis Endocrine disorders
Psychiatric eating disorders - Anorexia nervosa/Bulimia Hypogonadism - Gonadal dysgenesis
Chronic malabsorption (e.g. Celiac disease) Hyperthyroidism
Acquired immunodeficiency syndrome Cushing syndrome
Female athlete triad disorder Growth hormone deficiency
Delayed pubertyPediatric Rheumatology 2009, 7:16 http://www.ped-rheum.com/content/7/1/16
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A study by Aggarwal et al. [18] found decreased BMD in
adult patients previously diagnosed with JIA. Likewise,
Okumus et al. [19] found lower BMD levels in 30 JIA
patients, especially in the polyarticular group. While they
did not detect a statistically significant relationship with
disease duration, BMD and Z score were associated with
lower insulin-like growth factor I (IGF-I) levels. Hender-
son et al. [20,21] described low total body BMD (Z score
lower than -1SD) in 29.2% of prepubertal and postpuber-
tal JIA patients. Notably, none of the JIA patients or con-
trols had ever received GC. As noted, those with greater
disease severity and inflammatory markers were more
prone to have low BMD. Hartman et al. also demon-
strated osteoporosis by DXA and by ultrasound in chil-
dren with chronic rheumatic diseases [5]. It is important
to note that interleukin-6, an important cytokine in JIA,
especially systemic JIA, may be an important factor in the
development of OP by stimulating osteoclast activity, as
demonstrated in an interleukin-6 transgenic mice model
by De Benedetti et al. [22]
Clinically, OP may present with a painful bone fracture
often associated with mild trauma, whether in a child
with a chronic disease such as JIA, or in a previously
healthy child with a mild form of OI.
Osteoporosis in the pediatric age group carries little mor-
tality; however, it does bring a considerable burden of
morbidity, especially due to pain, interference with regu-
lar activities, and long-term sequele.
Treatment
While the guidelines for the treatment of OP in adults are
widely accepted, the much less abundant data for children
and adolescents with OP makes it harder to set clear
guidelines for the pediatric population.
Physical activity
It is currently acknowledged that the main factor for
achieving peak bone mass in any healthy individual is
genetically determined [23]. However, during the last two
decades, the notion that weight bearing physical activity
(WBPA) during childhood and puberty affects bone mass
and formation has become widely accepted. This critical
period in life affects bone health during later stages and
may promote or inhibit one's tendency to develop osteo-
penia and OP. Research on the effect of WBPA on bone
mineral density (BMD) in children and adolescents has
been on the rise for several years.
Rideout et al. [24] have shown that increased WBPA dur-
ing 12-18 years of age was directly correlated with BMD
and other factors examined in both lumbar vertebra and
the femur necks of healthy post-menopausal women.
Activity level at other ages was found to be much less sig-
nificant.
It may not be surprising that overall decreased physical
activity was found to be associated with decreased BMD in
a group of hemophilic children [25]. Likewise, Ausili [26]
reported decreased BMD in children with myelomenin-
gocele who were confined to a wheelchair compared to
those who were able to walk. In both groups, those who
participated in regular physical activity had higher BMD
levels than those who did not.
Lien et al. reported that when compared with healthy con-
trols, patients with early polyarthritis had low bone min-
eral content and low mineral contact gain that was
significantly associated with the level of weight bearing
exercise [27]. Alwis et al. [28] reported the effects of
increased physical education classes on lumbar vertebral
and femoral neck characteristics among healthy first and
second graders. Those participating in the study's inter-
ventional group had 3.3 times the amount of physical
activity as the control children. Using DXA, they found
that although no statistically significant changes were
found in the femoral neck, the width and bone mineral
content (BMC) of the L3 vertebra were increased in the
children who had more physical education classes. Simi-
larly, in a 7-year follow-up study of 142 adolescent girls,
increased physical activity was associated with greater
lumbar vertebral and femoral neck BMC. Although the
increase was modest, it was statistically significant [29].
The effect of activity on bone health also depends on
nutrition. Chevalley et al. [30] demonstrated that with the
same amount of energy expenditure at various physical
activities, prepubertal boys who consumed more protein
had a greater increase in BMD.
Calcium and Vitamin D
Daily oral intake of calcium is important for maintaining
adequate homeostasis and facilitating bone remodeling
and growth. The daily recommended intake (RDI) of cal-
cium changes with age, from 500 mg at 1-3 years, to 800
mg for 4 to 8 year-olds, and 1300 mg for 9-18 years of age
[31]. Many children and adolescents do not ingest enough
calcium to meet the RDI. Those at risk of OP should
receive calcium supplements to insure adequate intake.
In a meta-analysis performed by Winzenberg et al. [32] lit-
tle change in BMD was detected after calcium supplemen-
tation in healthy children. Still, patients with underlying
disorders affecting bone metabolism may receive greater
benefit from such interventions, as Carrasco et al. [33] and
Lovell et al. [34] have both demonstrated. By performing
two separate, double blind, randomized controlled trials,Pediatric Rheumatology 2009, 7:16 http://www.ped-rheum.com/content/7/1/16
Page 5 of 8
(page number not for citation purposes)
they were able to demonstrate a decrease in bone turnover
markers in JIA patients given supplemental calcium com-
pared to placebo. However, the increase of BMD in the
study of Lovell et al., was only slightly greater than with
placebo. In the study of Carrasco et al, vitamin D was also
provided for both the intervention and the control
groups. A simpler design utilizing increased dietary cal-
cium intake conducted by Stark et al. [35] found increased
BMC over a 6-12 month period in JIA patients aged 4-10
years.
The intake of appropriate levels of calcium alone may not
be enough. Evidently, the composition of the entire diet is
important for calcium utilization as shown by Seiquer et
al. [36]. They found that a Mediterranean-type diet
improved absorption and reduced secretion of ingested
calcium
Likewise, vitamin D is crucial not only for bone health
and maintaining serum calcium and phosphate levels, but
may also be involved in promoting innate immunity [37].
Vitamin D plasma levels in the general population have
been decreasing in recent years in response to reduced sun
exposure and outdoor activities, increased use of sun-
screen and less exercise. The RDI for vitamin D was
recently increased to 400 IU [38].
Bowden et al. [39] recently reported decreased levels of
25-hydroxyvitamin D levels among a large group of pedi-
atric patients with OP and osteopenia. Although no direct
connection with fracture risk was detected, they surmised
that vitamin D supplementation in children with osteope-
nia and OP is advisable and may indeed reduce morbid-
ity.
Similar findings were described in a follow-up study of 34
pediatric patients with acute lymphoblastic leukemia
(ALL) [40]. Although mean bone density was shown to
increase one year after therapy cessation, 1,25-dihydroxy-
vitamin D levels were lower among those suffering from
fractures compared to ALL patients without fractures dur-
ing the follow-up period.
Both Okumus et al. [19] and Bianchi et al. [41] found low
vitamin D levels in JIA patients treated with GC. They also
reported decreased BMD levels, resulting from high par-
athyroid hormone levels - the direct outcome of vitamin
D deficiency.
The recommended daily consumption of vitamin D may
not be sufficient for patients undergoing bone-affecting
treatments and those suffering from primary bone disor-
ders. Maalouf et al. [42] demonstrated that high-dose vita-
min D supplementation is safe. The efficacy of such a
regimen (manifested as higher levels of vitamin D and it's
metabolites in serum) was demonstrated by Kilpinen-
Loisa et al. [43]. Such therapy may augment bone density
and help prevent fractures and related morbidity.
The minimum blood levels of 25OH-vitamin D recom-
mended for patients with OP and patients receiving corti-
costeroids are 32 ng/ml or per some experts even 40 ng/
ml [44]. El-Hajj et al. [45] demonstrated that a high dose
of 2000 IU/day of vitamin D supplementation for one
year increased lean mass, bone area, and bone mass in
children.
Bisphosphonates
Bisphosphonates are a group of molecules analogous to
inorganic pyrophosphate. Unlike pyrophosphate,
bisphosphonates are resistant to normal enzymatic break-
down within human tissues. They concentrate within
bones, binding specifically to its inorganic components.
Bisphosphonates also enter osteoclasts and inhibit their
bone destruction ability via several cellular mechanisms.
The newer bisphosphonates, synthesized over the last
couple of decades, are much more effective than their
predecessors and affect bone growth to a much lesser
degree, making them more suitable for use in children
and adolescents. They are also pain modulators and have
anti-inflammatory properties through regulation of
inflammatory cytokines including TNF, IL-1, and IL-6.
Bisphosphonate therapy over a long duration seem to be
well-tolerated and safe according to two recent reviews by
Ward et al. [46] and Bachrach et al. [47] that included a
meta-analysis. Moreover, there seemed to be a consistent
benefit in terms of increased BMD among the trials
inspected.
Intravenous pamidronate appears to be useful for provid-
ing immediate pain relief resulting from fractures, mainly
vertebral, but its effectiveness in further decreasing the
fracture rate has not been proven; most data are from OI
treatment.
Poyrazoglu et al. [48] published their experience with 35
pediatric OI patients treated with IV pamidronate. After
treatment, these children had increased BMD scores,
decreased bone turnover according to lower bone turno-
ver markers, and decreased fracture rates. It was also con-
cluded that earlier age at onset of therapy was related to
better response and higher BMD readings. Growth was
not stunted by the bisphosphonate therapy. Moreover,
besides fever during the first treatment cycle, no other sig-
nificant adverse events occurred, making this a safe regi-
men.
Rauch et al. [49] conducted a double-blind placebo-con-
trolled study with oral risedronate for mild OI. After twoPediatric Rheumatology 2009, 7:16 http://www.ped-rheum.com/content/7/1/16
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years of treatment, serum bone resorption marker levels
decreased and BMD increased significantly compared to
the control group.
Streeten et al. [50] reported nine new cases of OP pseu-
doglioma (OPPG), a rare autosomal recessive disorder
resulting in congenital blindness and evolving OP. In
their article, four patients were receiving bisphosphonates
regularly with good response, as surmised from serial
BMD testing. Barros et al. [51] reported similar findings in
two brothers with OPPG treated for four years. They also
described a decrease in fracture events, citing the higher
BMD as clinically significant.
Apkon et al. [52] found a mean increase of 12-28% in
BMD at three different locations in three boys with mus-
cular dystrophy, treated with weekly oral alendronate.
Two of them were wheel-chair bound. Despite the small
cohort of examined patients, the study emphasized the
potential of such interventions.
Children who receive corticosteroids are at increased frac-
ture risk. Inoue et al. [53] performed a prospective, con-
trolled study with five children suffering from
autoimmune diseases. All participants had GC-induced
OP. Their therapeutic regimen consisted of IV alendronate
therapy at 3-month intervals for a total of two years in the
intervention group. Although femoral neck BMD
decreased over the period of the study, in those patients
receiving alendronate, it actually increased. They also
noted a decrease in serum bone turnover markers tested,
that correlated with the improvement in BMD. No adverse
affects were reported during bisphosphonate therapy.
There are various regimens: the dose of pamidronate is 1-
3 mg/kg/day once a month to once every 3-4 months, to
be used for severe pain from fractures. Usually there is dra-
matic pain relief. The outcome relating to fracture preven-
tion is not yet established. The optimal duration of oral or
intravenous therapy is not known. Acute mild adverse
effects include malaise, myalgia, bone pain, diarrhea, and
fever; all are transient and self-limited. Hypocalcemia,
hypomagnesemia, and hypophosphatemia are far less
common. Other uncommon side effects, like esophagitis,
have been reported [47]. Radiographs frequently demon-
strate "growth-lines" that have no clinical significance.
For primary prevention, use of bisphosphonates in chil-
dren receiving corticosteroids for chronic disease is lim-
ited and currently is not recommended [46].
A group of 15 ALL pediatric patients treated with high
dose GC regimens and diagnosed with OP participated in
a bisphosphonate therapy study conducted by Lethaby et
al. [54]. The duration of treatment ranged from 6 to 24
months by the end of which 14 of the 15 children had
improvement in their BMD Z-scores. The remaining
patient's score did not change. They also showed that
alendronate use did not alter height velocity, regardless of
therapy duration.
What happens to drug availability after therapy stops?
While bisphosphonates are rapidly cleared from the
blood (half-life of several hours), in bones they have a
substantially longer half-life, measured in years. Papapou-
los and Cremers [55] reported urinary excretion of
bisphosphonates in seven patients at a mean duration of
7.7 years after treatment was discontinued. This should be
taken into consideration when prescribing those drugs to
teenage girls, for the effect on fetal development has not
yet been fully determined. Existing data, although very
limited, do not suggest any adverse outcomes [56]. It is
possible that there are differences between various types
of bisphosphonates in regard to bone half-life, but that
has not been studied in young females.
Apart from that, it was shown by Waterhouse et al. [57]
that the beneficial effects are sustained well beyond the
course of treatment. In their follow-up, with a mean dura-
tion of 26 months, they found increased BMD (especially
vertebral), decreased fracture rates, and no compromise of
growth or kidney function.
Bianchi et al. [58] conducted a long term (up to 10 years)
follow-up study of 43 children who were treated with
alendronate for connective tissue disease (most were
treated with corticosteroids for a prolonged time). They
concluded that alendronate was safe, seemed to reduce
the risk of fractures, and increased Z-scores. It appears that
the effect of alendronate on BMD is independent of the
connective tissue disease activity [59], and that alendro-
nate may improve height gain velocity and bone mechan-
ical strength even when patients are treated with GC [60].
A possible major side effect of bisphosphonate is
osteonecrosis of the jaw, which was reported only in
adults [61,62]. Therefore, pre-assessment by a dental sur-
geon is suggested for evaluation of wisdom tooth extrac-
tion and delaying dental treatment until bisphosphonate
administration is stopped. A special consideration in ado-
lescence is orthodontic dental work.
Parathyroid hormone
A few years ago, the Food and Drug Administration (FDA)
approved the use of recombinant human parathyroid hor-
mone (rhPTH) for the treatment of OP. However, several
concerns have risen regarding the safety of such an agent,
especially in younger patients, owing to reports of the
development of bone tumors in rats [63]. Still, the con-
nection is not absolutely clear [64] and ongoing researchPediatric Rheumatology 2009, 7:16 http://www.ped-rheum.com/content/7/1/16
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supplies newer data which suggest a smaller risk of pri-
mary bone tumors from rhPTH use [65]. Extensive work is
yet to be done before rhPTH is part of the regular treat-
ment for OP in children.
In conclusion, there are still uncertainties regarding
bisphosphonate use in pediatric OP. Its effectiveness
regarding fracture prevention and length of maximal bone
mass gain, as well as its long-term effects and safety are
unknown.
Regarding the management of the introductory cases: for
case #1, physical therapy, enriched diet, and increased cal-
cium and vitamin D, with no use of bisphosphonates is
the preferred regimen. For case #2, treatment should be
the same, with the possible addition of bisphosphonates.
In severe cases of painful fractures, the use of bisphospho-
nates is justified.
An osteoporotic child has to be treated with a team
approach, including a lead pediatrician, a pediatric rheu-
matologist or endocrinologist who is familiar with OP
management, together with a radiologist, orthopedic sur-
geon, physiotherapist, dietician, psychologist, and nurse.
The goal is to improve the child's bone health, which has
lifelong implications.
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